Crizotinib is a first generation ALK TKI that targets ALK, c-MET [6], and ROS1 [7], which was approved by the Food and Drug Administration (FDA) for ALK+ NSCLC in 2011. The gene discussed is ALK; the disease is non-small cell lung carcinoma.